Sunday, 22 November 2026 Every SEC filing alert, by company
ALFAFINDER USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Iambic Therapeutics Q3 2026 Results: Net Loss of $38.5M, Loss Widens

Iambic Therapeutics, Inc. is an emerging growth company focused on AI-driven drug discovery, with lead candidates IAM1363, IAM217, and IAM-C1 in various stages of clinical and preclinical development. As of November 16, 2026, the company had 48,933,878 shares of common stock outstanding and is currently operating as a non-accelerated filer following its initial public offering.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue11.44.7
Profit before tax-38.5-21.5
Net income-38.5-21.5
EPS (diluted, $ a share)$-8.52$-5.24

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+141.9%
Operating margin-265.3%
Source

10-Q filed with the SEC, NASDAQ: IAM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Iambic Therapeutics, Inc.: key numbers

Share price
$13.11Close, Nov 20
Market cap
$698M
Shares outstanding
48.93MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Iambic Therapeutics, Inc.

All →
8:09 AM ET 8-K
Financial Results

Iambic Therapeutics Financial Results

Iambic Therapeutics reported third quarter 2026 financial results, highlighting a pro-forma cash position of $455 million following its IPO and upfront payments from AbbVie. The company reported year-to-date collaboration revenue of approximately $24 million and total operating expenses of $108 million. Key operational milestones included the launch of its Enchant v3 AI model and positive Phase 1/2 data for its HER2 inhibitor, IAM1363.

Term
Q3 2026

“Iambic’s mission is to make better technology for better medicines, and we believe that the past several months showed that at work across every part of our business. At ESMO, our updated clinical data showed the intracranial activity and tolerability for IAM1363, and we are preparing to start a registrational trial in 2027, subject to regulatory approval. We submitted the IND and have received a Safe-to-Proceed Letter for a Phase 1/2 trial for IAM217, our second wholly owned and platform-discovered candidate, with an anticipated IND submission for IAM-C1, our CDK2/4 inhibitor, close behind. We launched Enchant v3, a huge advance in the core AI technology that underpins our molecular superintelligence platform, and AbbVie and Bayer each chose to bring our platform to bear on their own discovery work through new Iambic partnerships. Our IPO gives us the resources to advance our pipeline through major inflection points and to keep scaling the platform behind it.”

Tom Miller, PhD, Co-Founder & CEO of Iambic
7:47 PM ET Form 4
Insider Buying

Iambic Therapeutics Director Evan Lockwood Rachlin Buys $11.5M of Stock

Evan Lockwood Rachlin, Director, bought 718,750 shares of Iambic Therapeutics, Inc. at $16.00 a share, worth $11.5M in total on Oct 16, 2026. Shares held after the trade: 2,588,248 (+38.4%).

Value
$11.5M
Shares
718,750
Price
$16.00
Role
Director
Holding change
+38.4%
Trade date
Oct 16, 2026
5:04 PM ET 8-K
Capital Raise

Iambic Therapeutics Capital Raise

Iambic Therapeutics, Inc. filed an amended and restated certificate of incorporation and adopted restated bylaws in connection with the completion of its initial public offering (IPO). The filing formalizes the company's corporate governance structure as it transitions to a publicly traded entity on the Nasdaq Stock Market.

Get Alerts

Get ALFAFINDER USA alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.